• Je něco špatně v tomto záznamu ?

Emerging biologic and clinical implications of miR-182-5p in gynecologic cancers

M. Zehtabi, F. Ghaedrahmati, MAG. Dari, F. Moramezi, B. Kempisty, P. Mozdziak, M. Farzaneh

. 2025 ; 27 (6) : 2367-2382. [pub] 20241211

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015583

MicroRNAs (miRNAs) have emerged as important regulators of gene expression in various biological processes, including cancer. miR-182-5p has gained attention for its potential implications in gynecologic cancers, including breast, ovarian, endometrial, and cervical cancers. miR-182-5p dysregulation has been associated with multiple facets of tumor biology in gynecologic cancers, including tumor initiation, progression, metastasis, and therapeutic response. Studies have highlighted its involvement in key signaling pathways and cellular processes that contribute to cancer development and progression. In addition, miR-182-5p has shown potential as a diagnostic and prognostic biomarker, with studies demonstrating its correlation with clinicopathological features and patient outcomes. Furthermore, the therapeutic potential of miR-182-5p is being explored in gynecologic cancers. Strategies such as miRNA mimics or inhibitors targeting miR-182-5p have shown promise in preclinical and early clinical studies. These approaches aim to modulate miR-182-5p expression, restoring normal cellular functions and potentially enhancing treatment responses. Understanding the biologic and clinical implications of miR-182-5p in gynecologic cancers is crucial for the development of targeted therapeutic strategies and personalized medicine approaches. Further investigations are needed to unravel the specific target genes and pathways regulated by miR-182-5p. It is important to consider the emerging biologic and clinical implications of miR-182-5p in gynecologic cancers.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015583
003      
CZ-PrNML
005      
20250731091110.0
007      
ta
008      
250708s2025 it f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12094-024-03822-9 $2 doi
035    __
$a (PubMed)39661239
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Zehtabi, Mojtaba $u Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
245    10
$a Emerging biologic and clinical implications of miR-182-5p in gynecologic cancers / $c M. Zehtabi, F. Ghaedrahmati, MAG. Dari, F. Moramezi, B. Kempisty, P. Mozdziak, M. Farzaneh
520    9_
$a MicroRNAs (miRNAs) have emerged as important regulators of gene expression in various biological processes, including cancer. miR-182-5p has gained attention for its potential implications in gynecologic cancers, including breast, ovarian, endometrial, and cervical cancers. miR-182-5p dysregulation has been associated with multiple facets of tumor biology in gynecologic cancers, including tumor initiation, progression, metastasis, and therapeutic response. Studies have highlighted its involvement in key signaling pathways and cellular processes that contribute to cancer development and progression. In addition, miR-182-5p has shown potential as a diagnostic and prognostic biomarker, with studies demonstrating its correlation with clinicopathological features and patient outcomes. Furthermore, the therapeutic potential of miR-182-5p is being explored in gynecologic cancers. Strategies such as miRNA mimics or inhibitors targeting miR-182-5p have shown promise in preclinical and early clinical studies. These approaches aim to modulate miR-182-5p expression, restoring normal cellular functions and potentially enhancing treatment responses. Understanding the biologic and clinical implications of miR-182-5p in gynecologic cancers is crucial for the development of targeted therapeutic strategies and personalized medicine approaches. Further investigations are needed to unravel the specific target genes and pathways regulated by miR-182-5p. It is important to consider the emerging biologic and clinical implications of miR-182-5p in gynecologic cancers.
650    _2
$a lidé $7 D006801
650    12
$a mikro RNA $x genetika $7 D035683
650    _2
$a ženské pohlaví $7 D005260
650    12
$a nádory ženských pohlavních orgánů $x genetika $x terapie $7 D005833
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a prognóza $7 D011379
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Ghaedrahmati, Farhoodeh $u Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
700    1_
$a Dari, Mahrokh Abouali Gale $u Department of Obstetrics and Gynecology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
700    1_
$a Moramezi, Farideh $u Fertility, Infertility and Perinatology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
700    1_
$a Kempisty, Bartosz $u Department of Human Morphology and Embryology, Division of Anatomy, Faculty of Medicine, Wrocław Medical University, Wrocław, Poland $u Department of Veterinary Surgery, Institute of Veterinary Medicine, Nicolaus Copernicus University, Torun, Poland $u Physiology Graduate Faculty North, Carolina State University, Raleigh, NC, 27695, USA $u Center of Assisted Reproduction Department of Obstetrics and Gynecology, University Hospital and Masaryk University, Brno, Czech Republic
700    1_
$a Mozdziak, Paul $u Physiology Graduate Faculty North, Carolina State University, Raleigh, NC, 27695, USA
700    1_
$a Farzaneh, Maryam $u Fertility, Infertility and Perinatology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. maryamfarzaneh2013@yahoo.com $u Clinical Research Development Unit, Imam Khomeini Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. maryamfarzaneh2013@yahoo.com $1 https://orcid.org/0000000162398745
773    0_
$w MED00180195 $t Clinical & translational oncology. $x 1699-3055 $g Roč. 27, č. 6 (2025), s. 2367-2382
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39661239 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091104 $b ABA008
999    __
$a ok $b bmc $g 2366438 $s 1252708
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 27 $c 6 $d 2367-2382 $e 20241211 $i 1699-3055 $m Clinical & translational oncology. $n Clin Transl Oncol $x MED00180195
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace